Supplementary Table S7 Most frequent adverse events in patients with PAH-SSc, PAH-SLE or PAH-MCTD/-CTD-other

Variable	PAH-SSc		PAH-SLE		PAH-MCT/CTD-other	
	Placebo N=91*	Selexipag N=77	Placebo N=37	Selexipag N=45	Placebo N=37	Selexipag N=45
Adverse events n	694	708	298	336	309	455
Patients with ≥1 adverse event n (%)	88 (96.7)	76 (98.7)	37 (100)	44 (97.8)	35 (94.6)	44 (97.8)
Patients with ≥1 serious adverse event n (%)	48 (52.7)	36 (46.8)	15 (40.5)	18 (40.0)	22 (59.5)	26 (57.8)
Patients with adverse event leading to discontinuation of study drug n (%)	12 (13.2)	15 (19.5)	2 (5.4)	7 (15.6)	1 (2.7)	10 (22.2)
Adverse event** n (%)						
Headache	31 (34.1)	42 (54.5)	11 (29.7)	33 (73.3)	18 (48.6)	29 (64.4)
Diarrhoea	25 (27.5)	35 (45.5)	11 (29.7)	16 (35.6)	6 (16.2)	16 (35.6)
Nausea	24 (26.4)	24 (31.2)	8 (21.6)	20 (44.4)	9 (24.3)	18 (40.0)
Worsening of PAH	40 (44.0)	21 (27.3)	9 (24.3)	9 (20.0)	13 (35.1)	9 (20.0)
Dizziness	16 (17.6)	17 (22.1)	8 (21.6)	9 (20.0)	6 (16.2)	9 (20.0)
Pain in extremity	4 (4.4)	17 (22.1)	2 (5.4)	5 (11.1)	2 (5.4)	9 (20.0)
Pain in jaw	7 (7.7)	15 (19.5)	1 (2.7)	6 (13.3)	-	-
Peripheral oedema	19 (20.9)	14 (18.2)	7 (18.9)	9 (20.0)	5 (13.5)	9 (20.0)
Dyspnoea	19 (20.9)	13 (16.9)	11 (29.7)	7 (15.6)	7 (18.9)	10 (22.2)
Upper respiratory tract infection	12 (13.2)	12 (15.6)	11 (29.7)	13 (28.9)	8 (21.6)	8 (17.8)
Back pain	6 (6.6)	11 (14.3)	4 (10.8)	3 (6.7)	-	-
Anaemia	12 (13.2)	10 (13.0)	-	-	3 (8.1)	5 (11.1)
Increased NT-proBNP	13 (14.3)	9 (11.7)	-	-	-	-
Myalgia	7 (7.7)	9 (11.7)	3 (8.1)	6 (13.3)	-	6 (13.3)
Right ventricular failure	11 (12.1)	8 (10.4)	-	-	-	-
Pneumonia	8 (8.8)	8 (10.4)	-	-	-	-

Nasopharyngitis	7 (7.7)	8 (10.4)	4 (10.8)	6 (13.3)	1 (2.7)	5 (11.1)
Urinary tract infection	6 (6.6)	8 (10.4)	4 (10.8)	2 (4.4)	-	-
Asthenia	4 (4.4)	8 (10.4)	-	-	-	-
Vomiting	-	-	6 (16.2)	16 (35.6)	1 (2.7)	13 (28.9)
Cough	-	-	6 (16.2)	6 (13.3)	9 (24.3)	4 (8.9)
Flushing	-	-	4 (10.8)	7 (15.6)	-	7 (15.6)
Insomnia	-	-	7 (18.9)	3 (6.7)	-	-
Chest pain	-	-	4 (10.8)	4 (8.9)	6 (16.2)	9 (20.0)
Systemic lupus erythematosus	-	-	4 (10.8)	4 (8.9)	-	-
Abdominal pain	-	-	1 (2.7)	6 (13.3)	-	-
Decreased appetite	-	-	4 (10.8)	3 (6.7)	4 (10.8)	8 (17.8)
Pyrexia	-	-	1 (2.7)	6 (13.3)	5 (13.5)	2 (4.4)
Constipation	-	-	5 (13.5)	1 (2.2)	-	-
Cellulitis	-	-	5 (13.5)	-	-	-
Epistaxis	-	-	4 (10.8)	1 (2.2)	-	-
Leukopenia	-	-	4 (10.8)	1 (2.2)	-	-
Abdominal distension	-	-	4 (10.8)	-	4 (10.8)	2 (4.4)
Syncope	-	-	4 (10.8)	-	4 (10.8)	2 (4.4)
Arthralgia	-	-	-	-	4 (10.8)	8 (17.8)
Palpitations	-	-	-	-	4 (10.8)	7 (15.6)
Hypokalaemia	-	-	-	-	2 (5.4)	7 (15.6)
Bronchitis	-	-	-	-	4 (10.8)	2 (4.4)
Hypotension	-	-	-	-	-	5 (11.1)
Pruritus	-	-	-	-	4 (10.8)	-

*Among the patients randomly assigned to the placebo group, two did not receive study treatment and were not included in the safety analysis set.
**Adverse events are listed for those that occurred in more than 10% of the patients in any study group during the double-blind period and up to 7 days after placebo or selexipag was discontinued.
CTD: connective tissue disease; MCTD: mixed connective tissue disease; PAH: pulmonary arterial hypertension; SLE: systemic lupus erythematosus; SSc: systemic sclerosis.